8-oxo-nonanoyl chloride | 61720-60-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 8-oxo-nonanoyl chloride
• 英文别名: 8-Oxononanoyl chloride；8-oxononanoyl chloride
• CAS: 61720-60-3
• 化学式: C₉H₁₅ClO₂
• 分子量: 190.67
• InChiKey: QCICYSXWFXFBND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-oxo-nonanoyl chloride 在 palladium on activated charcoal lutidine 、 氢气 作用下， 生成 8-oxo-1-nonanal
  参考文献：
  名称：

  Burgsthaler,A.W. et al., Synthesis, 1976, p. 767 - 768

  摘要：

  DOI：

文献信息

• Carbohydrate-glycolipid conjugate vaccines
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：US10588962B2

  公开（公告）日：2020-03-17

  The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

  本发明涉及一类基于碳水化合物的新型疫苗的合成和生物评估领域。这种新型疫苗由多模块结构组成，可将疫苗应用于各种病原体。这种方法可以制备出针对所有表达免疫原性碳水化合物抗原的病原体的疫苗。由于不需要将抗原碳水化合物与蛋白质共轭，共轭疫苗的热稳定性特别好。无需冷藏，这是基于蛋白质的疫苗的一个主要缺点。
• POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2827899B1

  公开（公告）日：2015-08-05
• PHOTOACTIVABLE NITROGEN BASES
  申请人：BASF SE

  公开号：US20180217498A1

  公开（公告）日：2018-08-02

  Compounds of the Formula (I), (II) and (III) wherein Ar is for example phenylene, biphenyleneor naphthylene, all of which are unsubstituted or substituted by C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, CN, OR 11 , SR 11 , CH 2OR 11 , COOR 12 , CONR 12 R 13 or halogen; R 1 , R 2 , R 7 and R 8 independently of one another other are hydrogen or C 1 -C 6 -alkyl; R 3 and R 5 together and R 4 and R 6 together form a C 2 -C 6 -alkylene bridge which is unsubstituted or substituted by one ore more C 1 -C 4 -alkyl; R 11 is hydrogen or C 1 -C 6 -alkyl; R 12 and R 13 independently of one another for example are hydrogen, phenyl, C 1 -C 18 -alkyl, C 1 -C 18 -alkyl which is interrupted by one or more O; n is 1-10; X is O, S or NR 10 ; A and A 1 are suitable linking groups; are suitable as photolatent bases.
• [EN] CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES<br/>[FR] VACCINS CONJUGUÉS HYDRATE DE CARBONE-GLYCOLIPIDE
  申请人：MAX PLANCK GESELLSCHAFT

  公开号：WO2013139803A1

  公开（公告）日：2013-09-26

  The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi- modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
• [EN] CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES<br/>[FR] VACCINS CONJUGUANT UN HYDRATE DE CARBONE ET UN GLYCOLIPIDE
  申请人：MAX PLANCK GESELLSCHAFT

  公开号：WO2013178236A1

  公开（公告）日：2013-12-05

  The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure wherein a carbohydrate antigen is covalently bound to a glycolipid adjuvant. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.